Merus N.V. (MRUS)

Oncology Corporate Profile

Stock Performance


Company Description

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to share several features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MCLA-117CD3 Biclonics®Acute Myelogenous Leukemia (AML)I
MCLA-128ADCC-enhanced Biclonics®Breast cancerI
MCLA-128ADCC-enhanced Biclonics®Colorectal cancerI
MCLA-128ADCC-enhanced Biclonics®Ovarian cancerI
MCLA-158ADCC-enhanced Biclonics®Colorectal cancerPreclinical
MCLA-117CD3 Biclonics®Myelodysplastic Syndrome (MDS)Preclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display